researchers at Massachusetts General Hospital in the U.S. have developed a new general anesthesia may be safer for the sickest patients. The results of their investigation, so far only performed in animal models, published in the journal Anesthesiology. "
The authors describe preclinical studies MOC-etomidate drug, an altered version of an existing anesthetic that does not cause the rapid fall in blood pressure cause the majority of anesthetics or prolonged suppression of adrenal gland activity, a problem with the original form of medicine .
explains Douglas Raines, director of the project, "we have shown that etomidate produce a version of it decomposes very rapidly in the body reduces the duration of adrenal suppression while retaining the benefit of etomidate to maintain blood pressure much more stable than other anesthetics. "
Experts say that almost all general anesthetic agents reduce blood pressure immediately after administration, which can have serious consequences for older patients and more severe. In these cases we used etomidate but because adrenal suppression may last hours or days to be used other agents, which requires close monitoring to prevent dangerous drops in blood pressure.
To find a more secure version of etomidate, the researchers mimicked the chemical structure other similar drugs, from other drugs easier to metabolize, adding a molecule that causes the natural enzymes break down more quickly the drug after operation.
The researchers conducted experiments in tadpoles and rats and showed that the new agent, MOC-etomidate anesthesia produced quickly and that animals also recovered quickly after completion of dosing. The study in rats found that the MOC-etomidate had little effect on blood pressure levels and did not affect adrenal activity, even when administered at twice the dose required to produce anesthesia.
The researchers suggest that because the study only examined the effect of a single dose of MOC-etomidate, your next step is to study the continuous infusion of the drug. They also note that you need to collect additional data from animal studies prior to evaluating the agent in human patients.
"If all goes well, we hope to provide a large dose of MOC-etomidate for induction of anesthesia and follow with a continuous infusion to maintain anesthesia without reducing blood pressure even in patients too ill. We also anticipate that patients wake up faster and with less sedation after surgery and anesthesia, "he says Raines.
0 comments:
Post a Comment